Skip to main content
. 2014 Jul 24;9(7):e102927. doi: 10.1371/journal.pone.0102927

Table 1. Clinical, pathological and molecular findings in 30 cases of GBM.

Case Age/Sex Location Size (cm) Treatment Survival (months) Ki-67 (%) EGFR expression Pattern of infiltration miR-200c 2-ΔΔCt EGFR wild/mutant
1 72/F F 6.0 RT+CH 8 14.4 3 Diffuse 0.38 EGFRvIII
2 63/F T 7.0 RT+CH 11 8.5 3 Diffuse 0.06 EGFRvIII
3 69/M T 6.0 NONE 6 10.4 3 Diffuse 0.26 EGFRvIII
4 48/M T 5.3 RT+CH 9 10.0 3 Not established 0.19 EGFRvIII
5 55/F CC 4.0 QT 4 14.0 3 Diffuse 0.60 EGFRvIII
6 58/F T 6.0 RT+CH 23 21.8 3 Diffuse 0.12 EGFRvIII
7 61/M T 8.0 RT+CH 11 1.6 2 Not established 0.26 EGFRvIII
8 59/F P 1.5 RT+CH 27 4.5 3 Diffuse na EGFRwt
9 66/M P 4.0 RT+CH 6 19.7 2 Not established 0.17 EGFRwt
10 55/M P 6.0 RT+CH 10 3.8 2 Diffuse 0.46 EGFRvIII
11 69/M T 6.0 RT+CH 13 50.0 2 Diffuse 0.29 EGFRwt
12 66/M P 3.0 NONE ? 10.1 3 Diffuse 0.30 EGFRvIII
13 61/F F 4.7 NONE 2 22.4 3 Diffuse 0.69 EGFRvIII
14 45/M P 6.0 RT+CH 14 0.4 1 Not established 0.65 EGFRwt
15 24/M T 2.5 NONE ? 13.0 1 Not established 1.44 EGFRwt
16 67/M T 7.0 RT+CH 9 33.5 0 Diffuse 0.57 EGFRwt
17 73/M P 5.0 RT+CH 3 19.9 0 Diffuse 1.33 EGFRwt
18 45/M P 2.5 RT+CH 12 6.8 2 Diffuse 1.02 EGFRwt
19 60/M P 4.0 NONE 5 0.8 1 Nodular 0.65 EGFRwt
20 72/F P 3.7 RT+CH 30* 0.0 1 Nodular 1.95 EGFRvIII
21 66/F F 6.0 NONE 2 5.1 1 Diffuse 1.49 EGFRwt
22 66/M T 4.0 RT+CH 22 6.1 0 Diffuse 0.83 EGFRwt
23 63/M F 4.0 RT+CH 36 23.0 0 Diffuse 0.63 EGFRwt
24 74/M O 4.0 RT+CH 13 49.7 2 Nodular 1.21 EGFRwt
25 60/M F 4.0 CH 18 3.0 1 Nodular 0.93 EGFRwt
26 55/M F 6.6 CH 27 0.8 0 Nodular 1.02 EGFRwt
27 75/M O 4.0 NONE 6 0.2 1 Diffuse 1.18 EGFRwt
28 74/M F 6.7 RT+CH 1 10,5 1 Nodular 1.12 EGFRwt
29 63/F P 8.0 RT ? 0.1 0 Diffuse 1.06 EGFRwt
30 67/M P 3.5 RT+CH 50* 7.5 0 Diffuse na EGFRwt

Cases 1–13: High level of EGFR amplification; cases 14–20: Low level of EGFR amplification; cases 21–30: no EGFR amplification. Sex: male (M), female (F). Location: frontal (F), temporal (T), parietal (P), occipital (O), corpus callosum (CC). Treatment: radiotherapy (RT), chemotherapy (CH). Survival: all cases are exitus except (*) that were alive at the end of the present study and (?) that are cases with unknown evolution. (na): non-available. EGFRwt: EGFR wild type, EGFRvIII: EGFR mutant.